Adaptimmune secures $225m of new funding

GLOBALCAPITAL INTERNATIONAL LIMITED, a company

incorporated in England and Wales (company number 15236213),

having its registered office at 4 Bouverie Street, London, UK, EC4Y 8AX

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Equity
ABBs-Block Trades

Adaptimmune secures $225m of new funding

Aidan Gregory
June 02, 2020 03:15 PM
Adaptimmune_PA_575_375
Stanford M.D/Ph.D. student David Purger, changes the media of retinal ganglion cells from a rat in the Monje Lab at Stanford University's Lorry I. Lokey Stem Cell Research Building in Palo Alto, California, on Friday, August 31, 2012. (Photo by LiPo Ching/San Jose Mercury News/MCT/Sipa USA) | MCT/SIPA USA/PA Images

Adaptimmune Therapeutics, the New York-listed UK biopharmaceutical company focused on cancer treatments, has raised $225m to fund further clinical trials for its immunotherapy treatments.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

EquityABBs-Block TradesUKUnited StatesAmericasEuropeNorth AmericaEMEA
AG
Aidan Gregory
Gift this article